Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724075 | 0.80 | BCHE (0.40) | ALDH1A1GAA | |
| SCHEMBL17369065 | 0.78 | DUT (0.36) | DUTADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL2482514 | 0.77 | THRB (0.37) | L3MBTL1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL20509851 | 0.76 | DUT (0.38) | DUTCYP24A1AHR | |
| SCHEMBL26107967 | 0.76 | AHR (0.49) | DUTCYP24A1AHR | |
| SCHEMBL20393801 | 0.75 | TDP1 (0.38) | L3MBTL1MEN1KMT2AADRB2GAA | |
| SCHEMBL6094890 | 0.75 | SMN1; SMN2 (0.36) | MEN1KMT2AALDH1A1GAA | |
| SCHEMBL5257422 | 0.75 | QPCT (0.45) | L3MBTL1LMNAMEN1KMT2AQPCT | |
| SCHEMBL21389227 | 0.74 | MLYCD (0.38) | L3MBTL1LMNAMEN1KMT2AQPCT | |
| SCHEMBL13929746 | 0.74 | CYP26A1 (0.36) | KMT2AADRB2ADRB1ADRB3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | DUT 1395/4885L3MBTL1 4202/4885LMNA 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.